THE U.S. FOOD AND DRUG ADMINISTRATION

US FDA approves Eyenovia's eye drug, Formosa Pharma says

Formosa did not provide details on the pricing or the brand name for the eye drops, while Eyenovia did not immediately respond to Reuters' request for comments. The U.S. FDA's approval came in following data from two late-stage studies conducted by Formosa in patients who had undergone cataract surgery.

More in THE U.S. FOOD AND DRUG ADMINISTRATION

U.S., AstraZeneca strike deal for Covid-19 antibody treatment touted by Trump

The agreement, under the Trump administration's Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population like those over 80 years old, the U.S. Department of Health and Human Services said.
Roche receives U.S. emergency approval for coronavirus vs. flu test

With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone.
Nestle to buy Aimmune, valuing allergy treatment maker at $2.6 billion

The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement. The price represents a 174% premium to Aimmune's closing share price on August 28 of $12.60.
Trump administration to purchase 150 million Abbott Covid-19 tests for $750 million

The portable antigen tests, which can deliver results within 15 minutes and will sell for $5, received emergency use authorization from the U.S. Food and Drug Administration on Wednesday.
U.S. FDA approves GlaxoSmithKline's blood cancer drug

GSK's belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement.
The U.S FDA designates Thermo Fisher Scientific's Oncomine Precision Assay a breakthrough device

The Oncomine Precision Assay on the Ion Torrent Genexus System is a next-generation genomic profiling solution that can allow every laboratory to deliver a genomic profile with a one-day, hands-free workflow.
AstraZeneca approaches Gilead about potential merger

AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients.